FOSAMAX PLUS

This brand name is authorized in Australia, Hong Kong, Mexico, New Zealand, Singapore, United States

Active ingredients

The drug FOSAMAX PLUS contains a combination of these active pharmaceutical ingredients (APIs):

1 Alendronic acid UNII 2UY4M2U3RA - ALENDRONATE SODIUM

Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality. Read about Alendronic acid

2 Vitamin D3 UNII 1C6V77QF41 - CHOLECALCIFEROL

In its biologically active form vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated. Read about Vitamin D3

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M05BB03	Alendronic acid and colecalciferol	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2194L, 2224C, 9012H, 9183H
Country: HK	Department of Health Drug Office	Identifier(s): 53914, 56397
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 094M2005
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12315, 13084
Country: SG	Health Sciences Authority	Identifier(s): 13152P, 13565P
Country: US	FDA, National Drug Code	Identifier(s): 0006-0270, 0006-0710